TrialBreast cancer research and treatment2023

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.

Binghe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.